Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes

被引:14
作者
Cortes, J [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源
CLINICAL LYMPHOMA | 2003年 / 4卷
关键词
acute myeloid lymphoma; BMS-214662; geranylgeranyl transferase; lonafarnib; prenylation; Ras pathway; tipifarnib;
D O I
10.3816/CLM.2003.s.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Farnesyltransferase inhibitors were initially developed as Ras inhibitors as they inhibit the prenylation necessary for Ras activation. It is clear now that their mechanism of action is more complex and probably involves other proteins unrelated to Ras. At least 3 drugs within this family have been investigated in acute myeloid leukemia, myelodysplastic syndromes, and other leukemias. These are tipifarnib (R115777, Zarnestra(R)), lonafarnib (SCH66336, Sarasar(TM)), and BMS-214662. The first 2 are administered orally, whereas BMS-214662 is given intravenously. These drugs are at different stages of development, and design of treatment schedules and methodology of the available studies are very different. Although most of the information is still preliminary, these agents have demonstrated clear evidence of clinical activity in these diseases and very favorable toxicity profiles. Several studies are still ongoing to better define the efficacy of these agents in the treatment of leukemias, as well as to determine the best schedules, the role of combination with other agents, and the role of these agents in different settings, such as the management of minimal residual disease. It is very possible that these agents will soon find their way to the ranks of established agents for the management of myeloid malignancies.
引用
收藏
页码:S30 / S35
页数:6
相关论文
共 37 条
[1]   Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules [J].
Ashar, HR ;
James, L ;
Gray, K ;
Carr, D ;
Black, S ;
Armstrong, L ;
Bishop, WR ;
Kirschmeier, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (39) :30451-30457
[2]   Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period [J].
Baudard, M ;
Beauchamp-Nicoud, A ;
Delmer, A ;
Rio, B ;
Blanc, CM ;
Zittoun, R ;
Marie, JP .
LEUKEMIA, 1999, 13 (10) :1481-1490
[3]   RAS and leukemia:: From basic mechanisms to gene-directed therapy [J].
Beaupre, DM ;
Kurzrock, R .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :1071-1079
[4]  
BOS JL, 1989, CANCER RES, V49, P4682
[5]  
Buchner T, 1997, Curr Opin Oncol, V9, P18
[6]  
CAMACHO LH, 2001, P AN M AM SOC CLIN, V20, pA79
[7]  
Cheson BD, 2000, BLOOD, V96, P3671
[8]  
Cortes J, 2002, BLOOD, V100, p793A
[9]   Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies [J].
Cortes, J ;
Albitar, M ;
Thomas, D ;
Giles, F ;
Kurzrock, R ;
Thibault, A ;
Rackoff, W ;
Koller, C ;
O'Brien, S ;
Garcia-Manero, G ;
Talpaz, M ;
Kantarjian, H .
BLOOD, 2003, 101 (05) :1692-1697
[10]  
Cortes J, 2001, BLOOD, V98, p594A